Most diabetic patients describe moderate to severe pain symptoms whose pharmacological
treatment is palliative and poorly effective. Cannabidiol (CBD) has shown promising results …

Cannabidiol (CBD), a phytocannabinoid compound, presents antidepressant and anxiolytic-
like effects in the type-1 diabetes mellitus (DM1) animal model. Although the underlying …

The incidence of chronic pain is high in the general population and it is closely related to
anxiety disorders, which promote negative effects on the quality of life. The cannabinoid …

Clinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of
cannabis that interacts with the serotonin (5-HT) 1A receptor, may possess analgesic and …

The prelimbic division (PrL) of the medial prefrontal cortex (mPFC) is a cerebral division that
is putatively implicated in the chronic pain and depression. We investigated the activity of …

Background: Despite the frequency of diabetes mellitus and its relationship to diabetic
peripheral neuropathy (DPN) and neuropathic pain (NeP), our understanding of underlying …

The antinociceptive action of cannabinoids in acute and inflammatory pain states have been
well-documented. There is also accumulating evidence suggesting that cannabinoids are …

Chronic neuropathic pain (CNP) is a vast world health problem often associated with the
somatosensory domain. This conceptualization is problematic because, unlike most other …

Medications that improve pain threshold can be useful in the pharmacotherapy of
Parkinson's disease (PD). Pain is a prevalent PD's non-motor symptom with a higher …

Cannabis has a long history of medical use. Although there are many cannabinoids present
in cannabis, Δ9tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) are the two …